Sun02172019

Robins Global News & Noticias



  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Trump Pence News
    Trump Pence News
  • Weather Alerts
    Weather Alerts

RobinsPost News Network

+ Larger Font | + Smaller Font

Globe NewsWire News Distribution Service

Press Release: FibroGen Appoints Maykin Ho, Ph.D., to Board of Directors


SAN FRANCISCO, Dec. 06, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced the appointment of Maykin Ho, Ph.D., as an independent director to FibroGen’s Board of Directors. 
“We are delighted to welcome Dr. Maykin Ho, an accomplished leader with a great breadth of knowledge in the biotechnology industry, as a new Board member,” said Thomas B. Neff, CEO. “Dr. Ho brings extensive experience in global strategy, finance, research, and marketing, and she will be an invaluable advisor as we continue to advance FibroGen’s multiple late-stage product programs, and move closer to the potential commercialization of roxadustat.”Dr. Ho has more than 30 years of experience in the healthcare and finance industries. She serves on the boards of directors for Agios Pharmaceuticals, Parexel International Corporation, the Aaron Diamond AIDS Research Center, and the Institute for Protein Innovation. Dr. Ho is also a venture partner of Qiming Venture Partners and a member of the Biotech Advisory Panel of the Stock Exchange of Hong Kong. She is a retired partner of the Goldman Sachs Group where she served as senior biotechnology analyst, co-head of healthcare for global investment research and advisory director for healthcare investment banking. Prior to Goldman Sachs, Dr. Ho held various managerial positions in licensing, strategic planning, marketing and research at DuPont-Merck Pharmaceuticals and DuPont de Nemours & Company. She was a postdoctoral fellow at Harvard Medical School and a graduate of the Advanced Management Program at The Fuqua School of Business, Duke University. Dr. Ho received a Ph.D. in Microbiology and Immunology and a B.S. from the State University of New York, Downstate Medical Center."I have known and worked with the FibroGen team over the years,” said Dr. Ho. "FibroGen continues to make progress on a diverse pipeline and is poised to become a fully integrated company.  I am honored to join the Board at such an exciting time in the company's growth and transformation."About FibroGen
FibroGen, Inc., headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People’s Republic of China, is a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company’s most...


Posted: 2018-12-06 09:00:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.






Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Press Release: FibroGen Appoints Maykin Ho, Ph.D., to Board of Directors | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

FibroGen Appoints Maykin Ho, Ph.D., to Board of Directors

Thu, 06 Dec 2018 01:20:00 GMT

today announced the appointment of Maykin Ho, Ph.D., as an independent director to FibroGen’s Board of Directors. “We are delighted to welcome Dr. Maykin Ho, an accomplished leader with a great breadt...

FibroGen Appoints Maykin Ho, Ph.D., to Board of Directors

Thu, 06 Dec 2018 01:12:00 GMT

today announced the appointment of Maykin Ho, Ph.D., as an independent director to FibroGen’s Board of Directors. “We are delighted to welcome Dr. Maykin Ho, an accomplished leader with a great breadt...

FibroGen Appoints Gerald Lema to Board of Directors

Tue, 19 Sep 2017 09:35:00 GMT

“We are pleased to be strengthening our board of directors with the ... muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fib...



Related Bing Web Search

  • No items found
  • Related News Story Videos From Youtube

    Copernikris - Marginations vs. Globulins [Explicit]


    Related Videos On: Copernikris - Marginations vs. Globulins [Explicit]


    Dahsyat..! Manfaat Minyak Lintah Papua ini Bikin Rudal Anda GEDE


    Related Videos On: Dahsyat..! Manfaat Minyak Lintah Papua ini Bikin Rudal Anda GEDE


    ARTIKEL KESEHATAN


    Related Videos On: ARTIKEL KESEHATAN


    INI LHO... 5 KANDUNGAN UTAMA MINYAK LINTAH PAPUA YANG BIKIN SI OTONG TAMBAH GEDE


    Related Videos On: INI LHO... 5 KANDUNGAN UTAMA MINYAK LINTAH PAPUA YANG BIKIN SI OTONG TAMBAH GEDE


    ARTIKEL KESEHATAN


    Related Videos On: ARTIKEL KESEHATAN






    Blow Us A Whistle

    Comments (Whistles) Designed By Disqus




    Company Information

    Official Content Providers











    PRIVACY POLICY

    We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
    © 2008-2019 RobinsPost (The Bird's Eye View Company) All rights are reserved.
    RobinsPost provides links to news sites based on their RSS feeds.
    All trademarks, copyrights, videos, photos and logos are owned by news sources.
    News stories, videos and live streams are from trusted sources.
    ROBINSPOST Is Proudly Made In America.
    Where Quality, Safety and Service Comes First.